Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totaling 6,135 shares, a decline of 53.9% from the April 30th total of 13,319 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 56,976 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

Hedge funds and other institutional investors have recently modified their holdings of the stock. SmartHarvest Portfolios LLC purchased a new position in shares of Genenta Science in the 4th quarter valued at approximately $26,000. Citadel Advisors LLC acquired a new stake in Genenta Science in the 3rd quarter valued at $41,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science in the 4th quarter valued at $328,000. Norges Bank acquired a new stake in Genenta Science in the 4th quarter valued at $337,000. Finally, Weiss Asset Management LP acquired a new stake in Genenta Science in the 4th quarter valued at $480,000. 15.13% of the stock is owned by hedge funds and other institutional investors.

Genenta Science Price Performance

Genenta Science stock traded up $0.62 during mid-day trading on Monday, reaching $1.65. 64,294,186 shares of the company’s stock traded hands, compared to its average volume of 1,375,243. Genenta Science has a 12-month low of $0.55 and a 12-month high of $10.00. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16. The stock has a 50 day moving average of $0.69 and a two-hundred day moving average of $1.11.

Genenta Science (NASDAQ:GNTA) last announced its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.28.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.